BR112022020376A2 - Antígenos específicos de tumor para leucemia mieloide aguda (lma) e usos dos mesmos - Google Patents

Antígenos específicos de tumor para leucemia mieloide aguda (lma) e usos dos mesmos

Info

Publication number
BR112022020376A2
BR112022020376A2 BR112022020376A BR112022020376A BR112022020376A2 BR 112022020376 A2 BR112022020376 A2 BR 112022020376A2 BR 112022020376 A BR112022020376 A BR 112022020376A BR 112022020376 A BR112022020376 A BR 112022020376A BR 112022020376 A2 BR112022020376 A2 BR 112022020376A2
Authority
BR
Brazil
Prior art keywords
aml
tsas
acute myeloid
tumor
specific antigens
Prior art date
Application number
BR112022020376A
Other languages
English (en)
Portuguese (pt)
Inventor
Perreault Claude
Thibault Pierre
Lemieux Sébastien
Ehx Grégory
Hardy Marie-Pierre
Original Assignee
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montreal filed Critical Univ Montreal
Publication of BR112022020376A2 publication Critical patent/BR112022020376A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022020376A 2020-04-14 2021-03-15 Antígenos específicos de tumor para leucemia mieloide aguda (lma) e usos dos mesmos BR112022020376A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009853P 2020-04-14 2020-04-14
PCT/CA2021/050340 WO2021207823A1 (en) 2020-04-14 2021-03-15 Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof

Publications (1)

Publication Number Publication Date
BR112022020376A2 true BR112022020376A2 (pt) 2022-11-22

Family

ID=78083452

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020376A BR112022020376A2 (pt) 2020-04-14 2021-03-15 Antígenos específicos de tumor para leucemia mieloide aguda (lma) e usos dos mesmos

Country Status (11)

Country Link
US (1) US20230287070A1 (enExample)
EP (1) EP4136099A4 (enExample)
JP (2) JP7822953B2 (enExample)
KR (1) KR20220167288A (enExample)
CN (1) CN115397842A (enExample)
AU (1) AU2021256477A1 (enExample)
BR (1) BR112022020376A2 (enExample)
CA (1) CA3173666A1 (enExample)
IL (1) IL296881A (enExample)
MX (1) MX2022012758A (enExample)
WO (1) WO2021207823A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7822953B2 (ja) * 2020-04-14 2026-03-03 ウニヴェルシテ ド モントリオール 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用
CN114045341B (zh) * 2021-11-30 2024-03-01 中南大学 口腔黏膜下纤维化恶性进展或其所致口腔癌的早期诊断和/或预后生物标志物的应用及产品
US20240013860A1 (en) * 2022-07-06 2024-01-11 Bioinformatics Solutions Inc. Methods and systems for personalized neoantigen prediction
EP4602051A1 (en) * 2022-10-11 2025-08-20 Université de Montréal Novel tumor-specific antigens for myeloid leukemia and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
EP2576614A4 (en) * 2010-05-24 2013-11-13 Phosimmune Inc CLASS I-MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
HRP20191671T1 (hr) * 2014-05-09 2019-12-13 Immatics Biotechnologies Gmbh Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20200967T1 (hr) * 2014-06-20 2020-10-16 Immatics Biotechnologies Gmbh Nova imunoterapija protiv nekoliko tumora krvi, posebice kronične limfoidne leukemije (cll)
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
EP3277841A1 (en) * 2015-03-31 2018-02-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml
US11524989B2 (en) * 2015-06-24 2022-12-13 Kling Biotherapeutics B.V. AML antigens and uses thereof
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
SG10202110335PA (en) * 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
TW202304970A (zh) * 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
TW201841937A (zh) * 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) * 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
MX2021002333A (es) * 2018-08-30 2021-04-28 Univ Montreal Metodo basado en proteogenomica para identificar antigenos especificos de tumores.
TW202024121A (zh) * 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
JP7822953B2 (ja) * 2020-04-14 2026-03-03 ウニヴェルシテ ド モントリオール 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用

Also Published As

Publication number Publication date
US20230287070A1 (en) 2023-09-14
JP2023521219A (ja) 2023-05-23
MX2022012758A (es) 2022-11-30
IL296881A (en) 2022-12-01
CA3173666A1 (en) 2021-10-21
JP7822953B2 (ja) 2026-03-03
CN115397842A (zh) 2022-11-25
JP2026009916A (ja) 2026-01-21
AU2021256477A1 (en) 2022-11-10
EP4136099A1 (en) 2023-02-22
EP4136099A4 (en) 2024-08-07
KR20220167288A (ko) 2022-12-20
WO2021207823A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
BR112016025035A2 (pt) imunoterapia contra diversos tumores hematológicos, como a leucemia mieloide aguda (aml)
AR118719A2 (es) Oligonucleótidos para reducir la expresión de pd-l1
MX2024006956A (es) Inserciones de adn no virales orientadas.
MX2018009853A (es) Ligandos de direccion.
BR112015031763A2 (pt) Compostos, composição farmacêutica e processos para melhorar ou tratar infecção viral e para inibir a replicação de paramixovírus e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
WO2017053431A3 (en) Allele selective gene editing and uses thereof
MX2017009324A (es) Erradicacion guiada por arn de herpes simple tipo i y otros herpesvirus relacionados.
MX390848B (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
EP3173092A3 (en) Rna containing composition for treatment of tumor diseases
BR112016028219A2 (pt) composto, método de tratamento ou prevenção do câncer, de uma doença infecciosa, ou de uma doença designada por aberração de metabolismo de energia celular em um indivíduo, método de tratamento ou prevenção de leucemia, câncer de pulmão de não pequenas células, carcinoma hepatocelular, ou glioblastomas em um indivíduo, método de tratamento de uma doença ou distúrbio em um indivíduo, composição farmacêutica e processo para obtenção de um composto de fórmula (i)
CY1122074T1 (el) Νεα παραγωγα 3'-δεοξυαδενοσινης του φωσφοραμαδικου εστερα toy 2' και/η 5' aminoξεος ως αντικαρκινικες ενωσεις
PH12018502606A1 (en) Phosphoramidate nucleoside derivatives as anticancer agents
BR112013005872A2 (pt) compostos, composição farmacêutica e respectivos usos
BR112016000810A2 (pt) imunoterapia contra vários tumores tais como câncer de pulmão, incluindo cpcnp
WO2016036994A8 (en) Method of analysis allowing avoidance of surgery
MX2022012758A (es) Novedosos antigenos especificos de tumores para leucemia mieloide aguda (aml) y usos de estos.
BR112017025698A2 (pt) composições e métodos para inibir a expressão do gene de hif2alfa
MX2024000277A (es) Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.
MX377211B (es) Composiciones terapéuticas para usarse en el tratamiento del cáncer.
BR112018007128A2 (pt) compostos para a inibição de câncer e epigênese
PH12021551817A1 (en) Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
WO2015100113A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
HK1252245A1 (zh) 用於治疗癌症的核苷酸
CU20170083A7 (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos útiles para el tratamiento de enfermedades asociadas al dolor, y para el tratamiento o profilaxis de los síndromes del dolor, de la endometriosis, la adenomiosis y el cáncer
MX2024003142A (es) Antigenos especificos de tumores novedosos para el cancer colorrectal y usos de estos.